About Insilico Medicine
Insilico Medicine is a publicly listed company based in Hong Kong (China) founded in 2014 by Alex Zhavoronkov and Stephanie Williams. AI-enabled bioinformatics is applied to drug discovery and biomarker development. It operates on a AI-as-a-Service and HealthTech model in Healthcare and Technology sectors. Insilico Medicine has raised $509.76 million across 12 funding rounds from investors including Juvenescence, WuXi AppTec and HHS. The company has 287 employees. Insilico Medicine was last valued at $1.7 billion in December 2025. Its chief executive, as recorded, is Alex Zhavoronkov. Its website insilico.com draws about 57 thousand monthly visits. Insilico Medicine offers products and services including PandaOmics, Chemistry42, Generative Biologics, inClinico, and Science42:DORA. Its focus areas include Biotechnology and Drug Discovery.
Company details
Insilico Medicine is engaged in transforming drug discovery and development through generative artificial intelligence. The company is involved in the healthcare and biotechnology sectors, offering solutions that significantly reduce the time and cost of bringing medications to patients. Various platforms like PandaOmics, Chemistry42, and Generative Biologics are developed for disease modeling, target discovery, and biologics design. Therapeutic programs targeting fibrotic diseases, cancer, and other conditions are discovered using AI and automation. Sustainability and longevity are also addressed through innovative approaches in their pipeline.
- Annual Revenue$56.32 M (USD)-34.54as on Dec 31, 2025
- Net Profit-$353.28 M (USD)-1958.98as on Dec 31, 2025
- EBITDA-$55.3 M (USD)-76.32as on Dec 31, 2025
- Total Equity Funding$509.76M (USD)
in 12 rounds
- Latest Funding Round$110M (USD), Series E
Jan 2025
- InvestorsJuvenescence
& 38 more
- Employee Count287
Products & Services of Insilico Medicine
Insilico Medicine offers a comprehensive portfolio of products and services, including PandaOmics, Chemistry42, Generative Biologics, inClinico, and Science42:DORA.
Software used for disease modeling and target discovery.
Platform utilized for generating novel chemical structures.
Tool employed for designing biologics using AI technology.
Software applied for optimizing clinical trial processes.
AI tool used for scientific research automation.
Apps and channels of Insilico Medicine
its YouTube channel Insilico Medicine has 4.37K subscribers and 30 videos.
Videos from Insilico Medicine
The most watched videos on Insilico Medicine's YouTube channel, Insilico Medicine (4.37K subscribers). Click a video to play it here.
More on Insilico Medicine.
Funding Insights of Insilico Medicine
Insilico Medicine has successfully raised a total of $509.76M across 12 strategic funding rounds. The most recent funding activity was a Series E round of $110 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $509.76M
- Total Rounds 12
- Last Round Series E — $110M
- First Round $195,076
(Apr 2014)
- Investors Count 39
Latest 10 of 12 funding rounds of Insilico Medicine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $110M | Series E | – | Value Partners, Pudong Venture Capital | – |
| Aug 2022 | $35M | Series D | – | Prosperity7 Ventures | – |
| Jun 2022 | $60M | Series D | – | Qiming Venture Partners | |
| Jun 2021 | $255M | Series C | – | Warburg Pincus | |
| Sep 2019 | $37M | Series B | – | Qiming Venture Partners | |
| Jun 2018 | $6M | Series B | – | WuXi AppTec | |
| Jul 2017 | $4M | Series A | – | – | – |
| Apr 2017 | $211,668 | Grant | – | – | |
| Dec 2016 | $2.76M | Series A | – | – | – |
| Mar 2015 | $100,000 | Grant | – | – |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of Insilico Medicine
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $1.7B (Dec 2025). 39 investors in total: 38 institutional and 1 angel.
Investors in Insilico Medicine
Insilico Medicine has secured backing from 39 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Juvenescence, WuXi AppTec and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| pdvc.com | ||||
Venture capital fund focused on enterprise tech, fintech, deep tech, AI, B2B, B2C, and medtech companies | prosperity7vc.com | Dhahran, Saudi Arabia | ||
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
Private equity firm focused on mergers & acquisitions | bhrpe.com | Beijing, China | ||
Multi-stage private equity investments are pursued across diverse sectors. | 1966 | warburgpincus.com | New York, United States | |
Early-stage life sciences and tech focused VC firm investing primarily in the US | boldcapitalpartners.com | Santa Monica, United States | ||
Growth-stage companies are invested in by this venture capital fund. | pavilioncapital.com | New York, United States | ||
Multistage investments are directed toward technology, healthcare, and climate sectors. | b.capital | Manhattan Beach, United States | ||
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Investments in early-stage biotech startups are made by Formic Ventures. | formic.vc | San Francisco, United States |
Investor details for Insilico Medicine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Insilico Medicine
55 people are tracked at Insilico Medicine (25 in leadership, 8 in board & advisors, 22 in team); the tracked headcount is 287.
| Name | Role | Group |
|---|---|---|
Alex Zhavoronkov | Co-Founder & Co-CEO | Leadership |
Stephanie Williams | Co-Founder | Leadership |
Feng Ren | Co-CEO | Leadership |
Joy Hu | Director Of Public Relations | Leadership |
Alex Aliper | Co-Founder & President | Leadership |
Min Fang | Managing Director of Healthcare | Leadership |
鑫 程 | Associate Director Of Medicinal Chemistry | Leadership |
Sujata Rao | Chief Medical Officer | Leadership |
Jimmy Yen-Chu Lin | CEO, Insilico Medicine Taiwan | Leadership |
Hui Wang (Sophia) | Head Of Inhalation/ Formulation Scientist | Leadership |
Jianwu Fang | Head Of In Vivo Pharmacology | Leadership |
Xing Liang | Director, Head Of CMC | Leadership |
Vladimir Aladinskiy | Head Of Computational Chemistry | Leadership |
Xiao Ding | Svp, Head Of Chemistry & DMPK | Leadership |
Luoheng Qin | Vice President Of Chemistry | Leadership |
Andy Min Xie | Head Of Hr, VP | Leadership |
Bei Zhang | Non- Oncology Medical Director | Leadership |
Joyce Z. | China HR Head | Leadership |
Igor Gavrilov | Head Of Creative | Leadership |
Deborah Sampson | Founder Of Anti-ageing & Wellness | Leadership |
35 more people are available in the full profile.
Complete people profiles for Insilico Medicine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Insilico Medicine
Insilico Medicine is a publicly listed company on the HKEX with ticker symbol 3696 in Hong Kong, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Dec 2025
- Listed onHKG: 3696
- Listed entityInSilico Medicine Cayman TopCo
- Exchange sectorCommercial services
- ISINKYG4790P1037
- Share price41.58 HKD (-4.68% on the day) · 2026-10-14
- Market capitalisation25,522,941,549.00 HKD
- EPS (diluted, trailing year)-4.18 HKD
- Volume (last session)9,089,383
Financials of Insilico Medicine
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 438.4M HKD | -2.75B HKD | -430.4M HKD |
| 2024 | 669.8M HKD | -133.4M HKD | -244.1M HKD |
| 2023 | 400.7M HKD | -1.66B HKD | -620.4M HKD |
| 2022 | 236.1M HKD | -1.74B HKD | -613.4M HKD |
| 2021 | 36.6M HKD | -1.01B HKD | -373.5M HKD |
Detailed financial statements for Insilico Medicine
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Insilico Medicine
5 dated milestones of Insilico Medicine across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Insilico Medicine is founded.
- Funding First funding round of $195K.
- Funding Latest funding round, Series E, of $110.0M.
- Milestone Reaches Unicorn status.
- IPO Lists on the stock exchange (IPO).
Web traffic of Insilico Medicine
The website of Insilico Medicine (insilico.com) receives about 57K visits a month.
- Monthly visits57K
▲ 23.9% vs previous month
Websites whose visitors overlap most with Insilico Medicine. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| criver.com | 100% | 224.6K | #186,811 | View details | |
genengnews.com | genengnews.com | 100% | #281,744 | – | |
| nature.com | 86% | 33.6M | #1,922 | View details | |
| pharma.ai | 70% | 14.1K | #1,848,975 | View details | |
| hkstp.org | 60% | #162,888 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Insilico Medicine
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Insilico Medicine
Complete news archive for Insilico Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Insilico Medicine
Insilico Medicine was founded in 2014.
Insilico Medicine is headquartered in Hong Kong, China.
Alex Zhavoronkov is the CEO of Insilico Medicine, as recorded in our data. They have also founded this company.
Insilico Medicine is a funded company, having raised a total of $509.76M across 12 funding rounds to date. The company's 1st funding round was a Grant of $100K, raised on Apr 2014.
Insilico Medicine has 287 employees.
Annual revenue of Insilico Medicine is $56.32M as on Dec 31, 2025.
Insilico Medicine is engaged in transforming drug discovery and development through generative artificial intelligence. The company is involved in the healthcare and biotechnology sectors, offering solutions that significantly reduce the time and cost of bringing medications to patients. Various platforms like PandaOmics, Chemistry42, and Generative Biologics are developed for disease modeling, target discovery, and biologics design. Therapeutic programs targeting fibrotic diseases, cancer, and other conditions are discovered using AI and automation. Sustainability and longevity are also addressed through innovative approaches in their pipeline.
Insilico Medicine offers PandaOmics, Chemistry42, Generative Biologics, inClinico, and Science42:DORA.
Yes, Insilico Medicine is publicly traded on HKEX under the ticker symbol 3696.
Insilico Medicine has 39 investors. Key investors include Juvenescence, WuXi AppTec, HHS, Warburg Pincus, and Orbimed.
The valuation of Insilico Medicine is $1.7B as of Dec 2025.
Insilico Medicine operates through Insilico Medicine.